Wound botulism occurs when a wound becomes colonized with clostridial bacteria under anaerobic conditions. Injection drug use — particularly black tar heroin — is a well-recognised risk factor. When the initial course of treatment does not stop the progression of paralysis within the expected timeframe, a next-line protocol is indicated.
The patient has wound botulism, with injection drug use (especially black tar heroin) as a risk factor. Wound botulism arises from clostridial colonization of an anaerobic wound and its management generally centres on debridement, addressing each patient's clinical situation.
First-line management included supportive care (with intubation and mechanical ventilation when necessary), wound debridement, and a standard adult dose of equine-derived botulinum antitoxin heptavalent (BAT) by intravenous infusion. The expected outcome of antitoxin therapy is that it stops the progression of flaccid paralysis — neurologic signs should not continue to progress for more than one day after administration. When that goal is not reached and clinical suspicion for botulism remains high, escalation to the next protocol step is warranted.
The next step involves a further administration of the same antitoxin by intravenous infusion, within a specified time window from the first dose. Specific eligibility criteria, timing requirements, and safety considerations govern this decision — the complete protocol details are available via the link below.
Risk factors for wound botulism include injection drug use (especially of black tar heroin) and for foodborne botulism include consumption of home-canned food.
Wound botulism is caused by clostridial colonization of an anaerobic wound, treatment of which is generally centered on debridement; treatment should address each patient's clinical situation.
Do not give patients with suspected botulism a second dose of BAT unless progression of paralysis clearly continues after the initial dose should have taken effect and suspicion for botulism is high.
In the highly rare instance in which it is clinically indicated, a second dose of BAT given within 2 weeks is unlikely to result in a hypersensitivity reaction related to sensitization caused by the first dose because it usually takes longer for the immune system to respond to a new antigen.
View source ↗